Genovese Burford & Brothers Wealth & Retirement Plan Management’s Aratana Therapeutics, Inc. PETX Stock Holding History

Genovese Burford & Brothers Wealth & Retirement Plan Management’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-1,250	Closed	-$5K	–	430
2018 Q2	$5K	Hold	1,250	–	–	﹤0.01%	365
2018 Q1	$6K	Buy	+1,250	New	+$5.58K	﹤0.01%	360

Other funds holding PETX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GAI

General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GPGA

Grandeur Peak Global Advisors Salt Lake City, Utah $427M AUM 39.14% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Genovese Burford & Brothers Wealth & Retirement Plan Management's PETX Position: Q3 2018 in Review

Genovese Burford & Brothers Wealth & Retirement Plan Management sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2018, closing a stake of 1,250 shares — an estimated $5K sold.

Genovese Burford & Brothers Wealth & Retirement Plan Management first reported a position in PETX in Q1 2018 and held it in 2 quarters. The position peaked at $6K in Q1 2018. 100 funds tracked by Wall St. Rank hold PETX as of Q3 2018.

Genovese Burford & Brothers Wealth & Retirement Plan Management reported no remaining Aratana Therapeutics, Inc. position as of Q3 2018 after selling out during the quarter.
Genovese Burford & Brothers Wealth & Retirement Plan Management sold 1,250 Aratana Therapeutics, Inc. shares in Q3 2018, an estimated $5K.
Genovese Burford & Brothers Wealth & Retirement Plan Management first reported a position in Aratana Therapeutics, Inc. in Q1 2018 and held it in 2 quarters.
Genovese Burford & Brothers Wealth & Retirement Plan Management's Aratana Therapeutics, Inc. position peaked at $6K in Q1 2018.
100 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2018.

Based on Genovese Burford & Brothers Wealth & Retirement Plan Management's 13F filing for Q3 2018, filed 13 Nov 2018.